TP53 and cancer: Further investigation of the underlying mechanism of toxic ROS generation by PIs in Onc-p53 NSCLC could lead to the identification of novel targets and improved combination therapies that potentiate the selective cancer cell cytotoxicity of PIs in Onc-p53 NSCLC cells and tumors.